Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...
Dx&Vx Accelerates Development of Universal COVID-19 Vaccine
* Emerging as a next-generation vaccine amidst global resurgence of COVID-19 * Expanding v arious pipelines other than universal COVID vaccine SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development progr...
Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines
* Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus mutations. SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapi...
Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success
* To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank * Planning to initiate global multinational clinical projects in digital therapeutics * Establishing a future medical system centered aroun...
Mr. Chong-Yoon Lim, Chairman of COREE Group emphasizes "Creative destruction and Healthcare 4.0" [New Year Message at X-Twitter SNS]
SEOUL, South Korea, Jan. 3, 2024 /PRNewswire/ -- Chong-Yoon Lim, Chairman of COREE group, President of Hanmi pharmaceutical company and Former Chairman of Korea Biotechnology Industry Organization (The largest shareholder group of Coree HK, Hanmi (KOSPI) and Dx&Vx (KOSDAQ), as well), highlighted ...
Dx&Vx co-develops a bio-healthcare big data platform with LG CNS
- Possessing human genome and microbiome data in all clinical stages - Becoming a global bio-healthcare big data platform company SEOUL, South Korea, Dec. 20, 2023 /PRNewswire/ -- Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS. Dx&Vx recently anno...
DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia
- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK - DxVx plans to proceed its own clinical trials in Asia, including Korea and China SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vacc...
DxVx, won the governmental project to develop diagnostic sensor kit for adult diseases
* National Project converging semiconductor and biotechnology SEOUL, South Korea, June 9, 2023 /PRNewswire/ -- DxVx announced today that it won the national project, 'Korea-led K-Sensor Technology Development for Market Leadership' supported by the Ministry of Trade, Industry and Energy and man...
DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president
- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for new drug - Accelerating value of the new drug pipelines SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointedYong Gu Lee as the new CEO and ...
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...
